Patriot Capital Supports SDS Rx’s Acquisition of Mission Critical Delivery Solutions


Patriot Capital, a multi-strategy middle market investment firm, is pleased to announce a new subordinated debt and equity co-investment in SDS Rx, an existing platform of HCI Equity. Patriot’s investment supported SDS Rx’s acquisition of Mission Critical Delivery Solutions.

Headquartered in Clark, New Jersey, SDS Rx is a supply chain solutions provider focused on the last mile healthcare market, specializing in the movement of pharmaceuticals from post-acute care pharmacies to patients, as well as the transportation of radiopharmaceuticals. Mission Critical positions SDS Rx to expand service to existing customers in new geographies and adds route density in select geographies. Mission Critical represents the second add-on acquisition for SDS Rx since HCI’s initial investment and Patriot’s investment in the platform positions the business to continue pursuing additional add-on acquisitions.

Tim Frend, a Managing Director at HCI, commented, “We are very excited to partner with Patriot on another platform. They are consistently a thoughtful, supportive, and constructive capital provider.”

For more information on this transaction or for any potential add-on opportunities, please contact: Jonathon Cope or Sean Bilbrough.